Mannatech wins patent suit
This article was originally published in The Tan Sheet
As result of litigation to protect its patented glyconutrient products Ambrotose complex and Advanced Ambrotose formulas, the Coppell, Texas-based dietary supplements marketer announces that the U.S. District Court for the Northern District of Texas entered a final judgment and permanent injunction against Boston Mountain Laboratories, banning the firm from making or selling certain products for the duration of several of Mannatech's U.S. patents. Specifically, Boston Mountain Labs cannot sell BML Glyconutrient Formula, Glyco-8 and Glycoessentials, among others. Last year, the firm won patent and trademark claims it brought against Glycobiotics International for its infringing product Glycomannan (1"The Tan Sheet" July 21, 2008)
You may also be interested in...
The U.S. District Court for the Northern District of Texas prohibits Green Life and Xiong Lo from making, selling or distributing products infringing certain of Mannatech's patents. The Coppell, Texas, firm said Dec. 18 Green Life and Xiong Lo had purchased the Glyco 8 supplement from Boston Mountain Labs, against which Mannatech already prevailed in a separate patent case (1"The Tan Sheet" Oct. 12, 2009, In Brief)
A federal judge rules Glycomannan by Glycoproducts International infringed on multiple patents held by Coppell, Texas-based Mannatech, according to Mannatech. The ruling by the U.S. District Court for the Northern District of Texas also entered a broad permanent injunction against Riggins, Idaho-based Glycoproducts to make, use or sell Glycomannan in the U.S., Mannatech says July 11. Mannatech sought the injunction following a trial jury ruling that Glycoproducts had only infringed one of two patents for Mannatech's Ambrotose glyconutrient supplement (1"The Tan Sheet" June 16, 2008, In Brief)...
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.